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1.  Introduction 
Simulation is a formidable tool to aid and complement real 
experimentation. It presupposes the availability of a “simulator”, i.e. a 
computer code that can be run to imitate the behaviour of the system of 
interest. Simulators make it possible to explore complex relationships 
between input and output variables and can be used in settings where 
physical experimentation is impossible, such as rare event risk 
assessment. They are also invaluable when only a few physical runs can 
be made due to their high cost. For these reasons the practice of 
complementing laboratory experiments or field observations with 
simulated ones has been steadily growing in recent years, and a large 
number of scientific problems in the aerospace industry and other 
engineering set-ups, as well as in finance, marketing and several other 
disciplines, nowadays are explored with the aid of computer simulators. 
The books by Santner, Williams and Notz (2003) or Fang, Li and 
Sudjianto (2005) provide a useful introduction. In a recent conference 
dedicated to computer experiments Steinberg (2009), starting from 
applications, reviews some of the main ideas that have been proposed for 
the statistical analysis and design of studies that use computer simulators, 
including a brief mention of validation of the simulator by means of real 
data. 
In this paper we intend to take a look at computer simulation in 
the context of clinical trials, paying special attention to the design aspects. 
One of the characteristic features of clinical trials is the well-known 
“individual-versus-collective ethics” dilemma. Potential harm to the 
subjects must be minimized, especially when they are patients presently 
under care and at the same time the trial must maximize the experimental 
information for the sake of future patients. As well as the ethical 
considerations, time and costs are also important. According to the Phrma 
2009 Annual Report (2009), the complex process of researching and 
developing new medicines takes an average of 10 to 15 years and can cost 
$1.2 to $1.3 billion. Besides, only an average of 1 in 5 new drugs gets 
approved for general use. The burden of paying for all necessary people 
and services is usually borne by the pharmaceutical or biotechnology 
company that wants to develop the agent under study. Over the last decade 
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the pharmaceutical industry has encountered a vast number of failures of 
trials for drug development due to inadequate trial design, wrong 
statistical analysis, mistakes in the chosen dosages etc. Thus, to  bring 
down the costs, prevent possible failures in future trials, reduce the trial 
time frame and avoid possible side effects in humans, researchers and 
drug companies have started to perform virtual experiments. Clinical trial 
simulation is asserting itself as an emerging technique, thanks also to the 
advent of new powerful software tools. The U.S. Food and Drug 
Administration have recommended that the industry expand and 
accelerate development of simulated clinical trials (FDA, U.S. 
Department of Health and Human Services, 2004). An important 
contribution is the collective volume edited by Kimko and Duffull (2003) 
which gives a general overview of simulation for clinical trials presenting 
a large number of case studies (see also Taylor and Bosch, 1990 and 
Holford et al., 2000). 
Despite understandable misgivings in non-experts, the idea that 
the functioning of the human body can be mathematically modelled and 
analyzed has been widely accepted in the scientific community at least 
since the second half of last century. Mathematical models and numerical 
methods are used to approximate physiological functioning, disease 
progress and drug behaviour in the human body, thus making computer 
simulation possible in the pharmaceutical/biomedical field too. However, 
simulation studies require proper protocols just like real trials, but at 
present a theory of simulated experimental design seems to be lacking. It 
is up to the medical statisticians to meet this challenge, and develop 
appropriate methodological tools.  
This paper is mainly of a review character and is entirely based 
on recently published research. The statistical issues involved in a 
simulated trial that we present are  
 planning the simulation,  
 modelling,  
 experimental design,  
 validation of the simulator.  
We begin in Section 2 with a selection of simulated trials from the 
medical literature. In Section 3 we examine the potential aims of a 
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simulation experiment. Simulation models used in the clinical context are 
examined in Section 4. In Section 5 we discuss the ensuing experimental 
design problems. Section 6 contains a brief introduction to the use of 
metamodels in medicine. Section 7 is dedicated to the issue of validating 
the simulator of a virtual trial, and the final section contains our 
comments.  
 
2. Applications of Simulated Trials 
The goal of this section is to show by means of examples the variety of 
purposes for which simulated trials have actually been employed in 
medical research in recent years with the aim of illustrating a broad 
spectrum of applications. 
  
2.1 Dosage optimization 
In a recent study (Ozawa et al., 2009) the authors perform trial simulations 
in order to evaluate the dose reduction strategy in patients with liver 
dysfunction of a clinically well established medication - called docetaxel - 
used to treat breast, ovarian, non-small cell lung and other types of cancer. 
Docetaxel clearance is decreasing in patients with liver dysfunction 
therefore it may be indispensable to reduce the dose for this kind of 
patients and a reduction strategy linked to the gravity of liver dysfunction 
has been proposed (Minami et al., 2009). Since it is difficult to have a 
sufficiently large number of these patients for a real clinical trial, because 
of the typical exclusion criteria, the authors of this paper use a number of 
dose-response models and a pharmacokinetic model of docetaxel in order 
to simulate drug exposure. “Survival” and “number of patients who had a 
particular side effect (febrile neutropenia)” were the two chosen 
endpoints. A Weibull model was used to express the time to drop-out and 
the patients‟ characteristics were simulated according to previous Phase II 
studies. The model was validated with Phase II data provided by Kunitoh 
et al. (1996) by comparing the predicted trial results obtained by the 
medians of simulation with the real data. The results of the clinical trial 
simulations suggested that it is possible to decrease toxicity via a reduced 
amount of docetaxel without loss of efficacy. 
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2.2 Dosage scheduling 
Albers et al. (2007) conducted a simulation study aimed at developing an 
age-suitable carvedilol dosing strategy for paediatric patients, since the 
well established dosing scheduling was uniform for all age groups of this 
kind of patients at the time of the study. Carvedilol is a non-selective beta 
blocker used for the treatment of hypertension and congestive heart 
failure. For this purpose, a pharmacokinetic model was developed based 
on data from a prospective, nonplacebo-controlled study. The model was 
used for simulations of different dosing strategies. Covariates were 
included via stepwise forward inclusion procedure. In order to evaluate 
the pharmacokinetic model the authors compared simulated and measured 
carvedilol concentrations. The findings of the paper suggest that, in 
general, higher doses of the carvedilol are probably required for younger 
patients with respect to body weight. However, it is worth underlining the 
authors‟ words: “Further randomized controlled trials are necessary to 
establish a safe and effective use of carvedilol in paediatric patients with 
congestive heart failure”. 
 
2.3 Understanding treatment effects in population 
studies 
Lee et al. (2010) have tried to gain a better understanding of the possible 
effects of vaccinating employees with the new H1N1 influenza vaccine 
through the development of a simulation model. In particular, they 
develop an agent-based computer model “consisting of a virtual 
population of computer commuter agents, each having a set of 
sociodemographic characteristics and behaviours, and which, like virtual 
people, moved among virtual households, workplaces, schools, and other 
locations every day and interacted with each other through simulated 
social networks” (Lee et al., 2010). The model outcomes were daily 
disease incidence, prevalence, clinic visits, work absenteeism, 
hospitalizations and deaths. The study shows the way in which several 
actions regarding vaccination may have an important impact during an 
epidemic especially in terms of the labour force. 
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2.4 Determining an efficient screening protocol 
Since a randomized controlled trial to assess the efficacy of screening for 
ovarian cancer is costly because ovarian cancer is a rare disease and its 
diagnosis requires surgery, Urban et al. (1997) simulated the effects of 
offering screening to a given population, i.e. a virtual cohort of women of 
age 50 (at the beginning of the 30-year screening period) in order to 
identify an efficient protocol. A stochastic model was developed with the 
aim of evaluating the cost-effectiveness, namely the ratio that measures 
the cost per year of life saved attributable to the screening strategy, of 
several alternative protocols involving transvaginal sonography and/or a 
cancer antigen/biomarker called CA 125. The model simulates the 
natural progression of disease, then considers a screening program and 
evaluates how the screening strategy used alters longevity and costs. 
Assumptions and inputs for the model (cohort characteristics, disease, 
detection, survival and cost components) were based on previous data 
and literature reports. The aim of the simulation model was to rank 
possible strategies of screening in terms of benefits regarding health and 
cost advantages. The study suggests that screening once a year by 
transvaginal sonography conditional on high (or rising) values of CA 125 
is more efficient than screening once a year by transvaginal sonography 
without considering CA 125. 
 The use of simulation models can be very fruitful as regards 
identifying questions to be addressed by a screening trial, as well as for 
suggesting screening strategies. 
 
2.5 Comparison of trial designs  
Simulation can be used to compare the properties of various experimental 
designs. Lockwood et al. (2006) used clinical trial simulation to select a 
robust design in order to test the hypothesis that a novel treatment was 
effective for Alzheimer's disease and therefore the primary aim of the 
study was to compare the power of several experimental designs to detect 
a treatment effect. Basing themselves on literature reports and previous 
Phase I data, the authors developed a  family of reasonable disease and 
drug models (as the true effect for the new treatment was not known at 
the time of the study) describing the time course of the Alzheimer's 
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disease assessment scale (i.e. a test that evaluates language, memory, 
attention, reasoning etc). The models included pharmacokinetic, 
pharmacodynamic, disease progression, and placebo components. An 
execution model expressing the expected percentage of patients 
remaining in the trial was used based on past experience of 1% weekly 
dropout. The simulation results allowed the research team to compare 
eight trial designs and one of those proved to be more efficient than the 
traditional one, leading to savings in time and costs. This design was 
implemented later in a real trial.  
 
2.6 Sample size determination 
Simulations are frequently used to explore the impact of sample size on 
the study results. For instance, Chabaud et al. (2002) have simulated 
several clinical trials to investigate the best compromise between safety, 
efficacy, drug regimen, and number of patients to include in a Phase III 
study of a bradycardic agent called ivabradine developed for the treatment 
of stable angina pectoris. The authors examined the use of a physiological 
model aimed at transforming a biomarker (heart rate) into a clinical binary 
outcome (“absent” or “at least one chest pain”). Moreover, they developed 
a therapeutic model which assumed that the reduction in heart rate 
decreased the risk of angina attacks in patients with coronary artery 
disease. They also developed a pharmacokinetic–pharmacodynamic model 
that governed the decrease in heart rate based on the data of a Phase I 
randomized study with twelve healthy volunteers and different doses of 
ivabradine. The peculiarity of this paper lies in the fact that the authors 
use an epidemiologic database in order to obtain real heart rate profiles 
instead of a simulated model, i.e. they resample patients from a patient 
database rather than creating virtual patients. 
The findings of the paper suggest that it is necessary to include 200 
patients per group (control placebo and treated group) under an alpha of 
5% and a power of 90% in order to detect a reduction of the risk of at 
least one chest pain in 15% of the treated patients. 
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3. Purposes of a simulated trial  
In the light of the applications, we overview some possible types of 
simulated clinical trials, according to their purpose. It goes without 
saying that similar remarks extend to simulation in areas other than 
clinical research.  
A virtual experiment may either be a complement to or take the 
place of a physical one. Let us first look at the most common case, in 
which simulation is an aid to real-life experimentation. Simulations may 
be run for 
  pre-trial purposes  
When run before a trial, simulation usually involves 
 testing several scenarios to evaluate the implications of the 
assumptions and / or testing various models for model selection. 
For instance Abbas et al. (2006) develop five simulation models of a 
clinical trial for evaluating the changes in cholesterol as a surrogate 
marker for lipodystrophy in HIV patients treated with different drugs. 
The models are based on different assumptions on treatment 
variability and cholesterol reduction over time. The primary aim of 
the paper is to validate and select the “best” model. Selection of the 
best model is based on the principle of parsimony and specific 
validation criteria proposed by the authors. 
 choosing the experimental design  
This typically means running simulations to assess the power of the 
test that we intend to perform once we observe the data, in order to 
recommend a given sample size when analytical calculations are not 
feasible. The common assumption is that there are no dropouts leads 
to underestimating the number or patients who need to be recruited to 
achieve a desirable statistical power. 
But simulations may also be of help in improving the very design of 
the experiment, for instance by exploring its convergence properties 
in the case of a sequential one, studying the impact of possible 
protocol violations that may occur in the actual trial, and also 
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changing the inclusion / exclusion criteria.  
Improvement of the experimental design can also be viewed as a post-
trial purpose in order to prospectively optimize the design of future 
physical trials. In Skolnik et al. (2008) the authors performed a trial 
simulation comparing the so-called 3+3 patients per cohort design to 
the novel “rolling six” design with the aim of reducing the execution 
time of paediatric Phase I oncology trials, which is long with respect 
to the completion time related to adult cancer. Clinical trial 
simulations and virtual patients characteristics were based on 
historical data from 14 completed Phase I oncology trials conducted 
by the Children‟s Oncology Group and Pilot Consortium between 
2000 and 2006. Of the 14 above-mentioned studies, 12 were judged 
suitable for investigating characteristics and timeline data for analysis. 
The study suggests that the new proposed design might decrease the 
duration of pediatric phase I oncology trials without increasing the 
risk of toxicity and, at the end of the paper, the authors state that they 
plan to prospectively evaluate the “rolling six” design in the upcoming 
generation of paediatric Phase I trials. 
 assessing what might happen in a trial yet to be conducted e.g. 
predicting the outcome of Phase (k+1) using data from Phase k. 
De Ridder (2005) illustrated a case study where the aim was to predict 
the outcome of a Phase III trial through data from two Phase II trials 
with five different doses. In particular the real data were related to 
two placebo-controlled double-blind Phase II dose ranging trials with 
patients treated for 4 weeks. Simulations were used in order to: 
 obtain the outcomes of the Phase III trial; 
 assess the robustness of an ongoing Phase III trial in the same 
context (patient variability, dose-response, drug-response); 
 assess the chance of achieving a clinically relevant response with 
a reduced dose as compared with those included in the trial. 
 extrapolation purposes  
As M. Sale states (in Bonate and Howard Eds, 2004), the dimensions 
across which one may extrapolate include: different species (e.g. 
mouse/rat/dog to human), time (from a trial to demonstrate clinical 
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efficacy with a small number of strictly selected patients to a full 
clinical study), endpoint (from a surrogate to a clinical endpoint, 
namely a characteristic that reflects how a patient feels, functions, or 
survives), population (e.g. healthy to patients, adults to paediatric), 
dose/dosing regimen. In all these cases, the domain of these 
simulated trials is outside what has been investigated so far. 
 An alternative scenario is when the virtual experiment is run 
instead of a physical one or interactively. Therefore, the simulated trial 
can be conducted: 
 in replacement of a real trial, to provide direct knowledge about the 
drug(s) under investigation. (Most of the trials of Section 2 seem to 
belong to this category.)  
 interactively with a real trial, to build knowledge about the “true” 
state of nature, while dynamically modifying the computer code to get 
closer and closer approximations to the real phenomenon under study. 
We shall discuss this case in the final Section of the paper. 
 
 
4. Simulation models 
Computer experiment models simulate scenarios that might arise in real 
situations. In a clinical situation, a simulation model will include at least 
three submodels: 
 an input-output (IO) model 
 a covariate distribution model 
 an execution model 
Input-output models  These are the models that describe the patient‟s 
response to the treatment in mathematical terms. They include 
pharmacokinetic, pharmacodynamic, disease progression models or a 
combination of these, and should incorporate all the available information 
about the treatment and/or the disease derived from biological 
considerations, previous trials and other reliable sources. 
Pharmacokinetics models describe how the body processes the drug 
(absorption, distribution, metabolism and elimination), while 
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pharmacodynamics specifies how the drug works in the body. The time 
course of drug action in the body can be understood in terms of 
pharmacokinetics and pharmacodynamics (both in the absence or the 
presence of a disease). Disease progression models account for the time 
course of the disease in treated and untreated conditions. In particular, 
these models include a baseline disease status, a placebo response, a 
natural history component, namely in the absence of treatment the model 
should define the history of the disease, while in the presence of a 
particular treatment the disease status is modified and therefore the 
disease model should also take into account an active effect (for a 
thorough discussion see Chan and Holford, 2001).  
Examples of input-output models can be found in Duffull et al. 
(2000), Pillai et al. (2004), Gruwez et al. (2007), Zierhut et al. (2008), 
Habtemariam et al. (2009). However, other types of simulation models 
can be used such as agent-based models, which are based on simulating 
the behaviour of individuals and the overall consequences of their local 
interactions (see for example Lee et al. 2010), physiology models (see 
Chabaud et al. 2002) etc.  
 A word of warning: features of a model that are not relevant to the 
questions that have been posed from the simulation team should not be 
considered. For instance, even though “weight” could be a covariate of 
primary importance for a real trial, if the virtual experiment we want to 
conduct regards the same weight group, we should not include “weight” in 
the model. This may seem a fairly obvious statement, but in real life it is 
frequently violated. 
Covariate distribution models:   Input-output models usually include 
terms for covariate effects (prognostic factors), as models used for 
simulation studies must deal with the variability from individual to 
individual. Covariate distribution models describe in a probabilistic way, 
on the basis of previous trials or clinical experience, the variability of 
patients‟ demographic and physiological characteristics in the population 
of interest that might affect the response. Given an input-output model, 
the covariate distribution may be changed to reflect different 
characteristics in another population. Therefore, the impact of the 
different covariate distribution(s) on the expected outcome of a simulated 
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trial can be assessed, thus making it possible to explore conditions that 
have been ruled out in the inclusion/exclusion procedures of the actual 
trial. 
Execution or drop out models:  Although the protocol of a clinical trial is 
a binding document, it is well-known that some deviations from protocol 
are inevitable, due to patients dropping out, patients‟ non-compliance, 
patients lost to follow-up etc. (but also due to acquiring subsequent 
information which was not available when the study protocol was 
written). In simulation, execution models describe uncontrollable factors 
leading to deviations from protocol and therefore can be extensively used 
as a tool for anticipating weaknesses and limitations in a proposed study. 
Indeed, consequences of protocol deviations such as insufficient statistical 
power and patients‟ discontinuation can be studied via modelling and 
simulation techniques. A simple example is a dropout model in Lockwood 
et al. (2003) describing a random 3% weekly dropout rate derived from 
previous studies. Girard et al. (1998) develop a Markov execution model 
for patients‟ non-compliance assuming that the probability of taking a 
wrong dose (or not taking any dose at all) at a given time depends on the 
number of doses taken at the previous dose timing. Wang, Husan and 
Chow (1996) propose statistical models in the case of multiple dose 
regimen trials aimed at studying the impact of two different non-
compliance scenarios: patients who do not take the prescribe dosage or 
patients who do not adhere to the dosing schedule. 
 For a discussion of execution models see also Girard (2005). 
 
5. Experimental designs for simulation  
In the Western world and the major developing countries, guidelines for 
the correct conduct of a clinical study have been issued by authoritative 
regulatory agencies. In drug development studies, a joint regulatory-
industry initiative is the Technical Requirements for Registration of 
Pharmaceuticals for Human Use by the International Conference on 
Harmonization (ICH). A protocol is demanded for every trial, aimed at 
assuring safety and health of the trial subjects, and also adherence to the 
same standards by all study investigators, since most trials are multicentre 
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ones. In particular, the most important design decisions of the protocol 
may involve: 
- the choice of the treatments, which for most trials include one or 
more controls. 
- the eligibility criteria (inclusion/esclusion of potential subjects) 
and the sampling rule. 
- the sample size. When the design is carried out sequentially, this 
is replaced by the stopping rule.  
- the allocation rule of the subjects to the treatment arms. Very 
often this rule has a randomization component in it. 
- the use of blinding or double blinding i.e. masking the treatments 
to the subjects and often to the investigators as well. 
 One can safely assume that there are no ethical problems involved 
in simulated trials, and the costs are often a minute fraction of those of a 
real trial, so is a “protocol” for virtual trials still necessary? We maintain 
that it is, for instance in all the cases described in Section 3, a simulation 
plan approved by the research team would be needed, although it might be 
different from what a real experiment would require. The document 
should specify, for instance: 
- questions that have to be answered via the simulation  
- assumptions 
- description of the virtual experiment 
- statistical methods and analyses  
- suitable data to support the simulation model 
- techniques for model validation  
- extrapolation questions. 
The primary focus in the preparation of a simulation plan is to identify the 
question(s) that the project team wants to answer by the simulation 
experiment, but there are further advantages, as Kimko and Duffull (2003) 
state: 
 A simulation plan may work as a communication tool, especially 
in the model-building procedures where many assumptions should 
be listed in the plan.  
 It should convey a level of transparency that allows any or all of 
the work to be reproduced or continued by newly added persons 
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to the simulation team.  
 In addition, the simulation plan can provide a pro forma for the 
development of similar drugs or similar types of trial designs.  
 Approved simulation plan adds credibility and acceptance of the 
clinical trial simulation process.  
In simulation too there is scope for designing the experiment 
efficiently so as to gather information in the best possible way, so we 
now move on to discuss the experimental plan itself. The design and 
analysis of deterministic computer experiments has a vast literature (see 
for instance Santner, Williams, and Notz, 2003 or Fang, Li and 
Sudjianto, 2006). The design consists in choosing the settings of the 
input variables, with the proviso that a deterministic simulator provides 
“observations” without error, so replication is pointless. Space-filling, 
Latin Hypercubes, Minimax and Maximin Distance criteria, Uniform 
designs are used in a non-model based approach, and special analysis 
procedures such as the Kriging methodology are employed (Santner, 
Williams, and Notz, 2003). 
However, the simulator of a clinical trial – the input-output model, 
as well as the covariate model and the execution model – will very likely 
include a stochastic component and the rationale for using standard 
statistical tools, in particular, standard experimental design theory, is 
restored.  This includes traditional design techniques going back to 
Fisher, based on replication, randomization and blocking, and/or design 
optimality criteria (see for instance Atkinson, Donev and Tobias, 2007). 
Here it is worth mentioning that several papers address the problem of 
determining optimal experimental designs for pharmacokinetic-
pharmacodynamic models: (see for instance Duffull et al., 2005, 
Ogungbenro et al., 2007, McGree, Eccleston and Duffull, 2009). 
In addition, if simulating is cheap, we can expand the range and 
possibilities of the trial design. For a start, the choice of the covariate 
levels is under the experimenter‟s control and this allows for exploring 
conditions that have been ruled out in the inclusion/exclusion procedures 
of the actual trial exploring in depth all possible levels of the 
concomitant variables. The full strength of simulation lies in being able 
to treat prognostic factors as random noise in the simulated experiment, 
and letting them vary according to a prescribed probability law, whereas 
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in an actual trial we would have to content ourselves with just a few set 
levels, either chosen by the experimenter or occurring by pure chance.  
As regards factors of interest, we can experiment on a wider 
design space and/or increase the number of factors that are 
simultaneously tried and their levels. When simulating, we would 
normally not confine ourselves to fractional factorials but use full 
factorials instead. An important point is that the usual rules of factorial 
experiments apply, namely we should not vary the factor levels one-at-a-
time, to avoid masking possible interactions, not just possible 
interactions among the experimental factors (e.g. dosage and dose timing 
of the drug) but also possible interactions between treatments and 
prognostic factors. In actual practice often only a subset of factors proves 
to be responsible for most of the output variation, but not much use is 
made by clinical triallists of the literature on screening experiments, i.e. 
experiments for choosing a few relevant factors out of a potentially very 
large number (see Dean and Lewis, 2006). It is also sensible to use 
simulation for detecting possible side effects, and for accounting for 
possible protocol deviations. 
 Sequential design deserves special attention. Most real clinical trials 
are extremely lengthy.  Recruitment is typically sequential – patients join 
the trial one by one – and very slow. Results too become available 
serially. Thus in general trials are conducted sequentially on groups of 
patients and interim analyses of the data are performed. Adaptive designs 
have come into use: adaptation of the study protocol involves changes in 
sample size, changing doses, dropping treatment arms, changing the 
timing and number of interim analyses, etc. Clearly the crucial inferential 
problem is to assess the impact of such changes on the statistical analysis 
(Bauer and Köhne, 1994, Posch, Bauer and Brannath, 2003, Cui, Hung 
and Wang, 1999). Going from real to virtual, it makes sense to ask 
ourselves whether a simulated trial in clinical research should or should 
not be carried out sequentially, since the above mentioned issues (slow 
patient recruitment to the trial, side effects, ethical demand of early 
stopping, etc.) do not apply to computer experiments. One possible 
answer is that sometimes the sequential nature of the experiment is 
dictated by inferential aspects, e.g. recursive estimation of unknown 
parameters of the model in binary response comparative trials (see for 
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instance Hu and Rosenberger, 2006) or non-parametric convergence to 
the unknown MTD in the Up-And-Down experiments for Phase I (see 
Bortot and Giovagnoli, 2005). The severe handicap of the generally slow 
convergence of the algorithms is no longer a problem when the 
experiment is a simulated one. 
 As a final thought, we like to add that often the choice of the 
simulator itself is the output of a trial-and-error process that can be 
regarded as a virtual experiment. In other words, maybe we should also be 
looking into techniques of experimental design for choosing the simulator 
as well, and use, for example, designs for model-selection (as in Atkinson, 
Donev and Tobias, 2007). 
 
 
6.  Metamodels 
The requirement for the input-output model to be accurate in describing 
the problem under investigation means that the simulator may be rather 
complex. In some instances the simulator consists of the simultaneous 
solution of a large number of linear or non-linear, ordinary and/or 
differential equations and, consequently, running it does take up an 
appreciable amount of computer time or other resources. A possible 
solution consists in employing so-called emulators or surrogates, i.e. 
simpler models which represent a valid approximation of the original 
simulator. Since emulators imitate the original simulator, which is itself a 
model of reality, they are often called metamodels. One of the 
fundamental characteristics of these surrogate models is computational 
speed.  
   Furthermore, the case where data cannot support estimating all of the 
parameters in a complicated simulation model is not rare. Therefore, 
models with fewer parameters should be fitted to the data. In a study by 
Pillai et al. (2004), the authors state that “Although the complex 
physiological PK-PD model described the data well, its major 
disadvantages were the long computer run-times […] and the numerical 
difficulties associated with solving a rather stiff problem”. In order to 
reduce the computer run-times associated with the simulator, the authors 
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have constructed a „kinetics of drug action‟ (K-PD model) and its 
performance was assessed by fitting data simulated with the PK-PD model 
under various scenarios. The authors observe that the simplified model 
was virtually indistinguishable from the complex one.  
   Another use of metamodels in clinical research is to be found in 
Kowalski and Hutmacher (2001), who decided to adopt a one-
compartment model instead of a two-compartment one to face the 
problems arising from a sampling design that, due to logistic reasons and 
clinical convenience, was inadequate for the more complex model.  
 
 
7. Validating simulated trials: some examples 
Especially in the context of clinical trials we need to make sure that the 
simulators i.e. the models we use are “reasonable”. The key issue is 
whether a particular simulator is an adequate representation for the real 
system it is trying to represent, and consequently the question of its ability 
to accurately predict real situations. This concern is related to model 
verification and validation (e.g. see Sargent, 2008).  Model verification is 
concerned with mistakes that may occur in the computer program of the 
model and its implementation, while model validation is usually defined 
to mean “substantiation that a computerized model within its domain of 
applicability possesses a satisfactory range of accuracy consistent with the 
intended application of the model” (Schlesinger et al., 1979). Thus, the 
primary aim of validation is to make the model useful in the sense that it 
addresses the right problem and provides accurate information about the 
trial of interest. It goes without saying that to a certain extent this question 
arises in real experiments too, since real data too are subject to error, but 
in most cases we are inclined to believe that a real experiment has 
“empirical validity”, whereas a simulated one is fictitious and therefore 
far away from reality. When real data provided by physical experiments 
are taken to be the “gold standard” of the true relationship between factors 
and outputs, they should be used to confirm the computer model and the 
results obtained by simulation. In some cases, experimental data may not 
be available and data derived from observational studies or surrogate data 
(e.g. derived from experiments on animals or prototypes) may be used. 
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We can distinguish between retrospective and prospective 
validation. The so-called prospective validation is the one that uses data 
from simultaneous or subsequent clinical trials in the same context (e.g. 
same disease). Retrospective external validation uses the data of earlier 
trials to validate the model and, if necessary, modify it in order to present 
higher degree of credibility and confidence. Sometimes it is even 
possible to collect a new dataset for validation. If not (e.g. studies of rare 
diseases), an internal validation is used, which is based on “cheap” 
methods such as data-splitting, where data utilized in order to build the 
simulator are compared with data generated by the model. The validation 
problem is tackled with the aid of a family of resampling methods, at the 
expense of further computations. 
 Concordance of simulated with real data under the same study 
design can be performed via: 
 the use of graphs (or descriptive statistics), e.g. predicted 
versus observed dependent variable, residuals versus  
predicted values of the dependent variable; 
 metrics (e.g. standardized distances); 
 a posterior predictive check; 
 statistical check methods (e.g. chi-squared or 
Kolmogorov–Smirnov tests). 
In what follows we describe the validating methodology applied in some 
simulation projects taken from the literature.  
 In the carvedilol dosing strategy study described earlier (see 
§2.2), Albers et al. (2007) make use of a visual predictive check in order 
to evaluate the proposed simulation model: plasma concentrations 
(dependent variable) from 17 real patients were observed and compared 
with the simulation data. The authors observe that about 90% of the real 
data are within the 90th percentile of the simulated concentrations. The 
precision of the unknown parameter estimates of the pharmacokinetic 
model was assessed by establishing 95% confidence intervals using a 
bootstrap analysis. 
 Eddy and Schlessinger (2003) validate the so-called Archimedes 
diabetes model, namely a representation of the anatomy, treatments and 
outcomes related to diabetes, by comparing Kaplan-Meier curves of real 
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and virtual data. In particular, they examine whether the difference 
between the outcome of the actual trial and the model is statistically 
significant by using the corrected chi-squared and the correlation 
coefficient between the outcomes calculated by the model and the 
outcomes of the real trial.  
Duffull et al. (2000) develop a pharmacokinetic model for 
ivabradine and they use two different kinds of datasets in order to test its 
ability to describe the real data: all the observations used for the 
construction of the model and data were collected from a different study 
regarding 12 subjects. The authors state “The posterior predictive 
performance is a test of the degree of similarity between the system 
model and the system itself. It is performed by simulating data from the 
model under the same experimental design that the original data was 
obtained. Ideally, the simulated data should exactly represent the 
observed data. […] We have assessed the predictive performance by 
inspection of the prediction plots visually and comparing the cumulative 
density functions of the simulated and observed using a Kolmogorov–
Smirnov test for two samples”.  
Abbas et al. (2006) propose an innovative approach for the 
validation and selection of a simulation model based on the standardized 
distance, in mean and variance, between real and simulated data.  
In engineering problems, several papers address the problem of validating 
the computer model via Bayesian techniques. For instance Bayarri et al. 
(2007) introduce a fully Bayesian approach for modelling the bias 
between the computer model and the physical data. See also Wang, Chen 
and Tsui (2009) and Kennedy and O'Hagan (2000) among others, but in 
the clinical context a Bayesian approach for validation does not appear to 
be as widely used.  
There may also be alternative ways for validation that have never 
been explored so far, e.g. tests for agreement (2004).  
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8. Some challenges 
Undoubtedly the successful execution of a simulation project requires a 
multi-disciplinary approach: interaction and cooperation are needed 
among scientists from various disciplines (clinicians, statisticians, 
computer scientists) and institutions (e.g. regulatory agencies and 
industry). The recent interest shown by pharmaceutical companies in 
clinical trial simulation poses several challenging questions: 
 Scientificity: Is this new discipline rigorous enough? Can results 
obtained by computer experiments be trusted?  
 Efficacy: Is it true that simulated clinical trials can speed the 
drug development process? After all, the model development 
procedure too is associated with time and high costs.  
 Ethics: Is it safe for the patients? Is it to their best advantage? Or 
do these efforts only help the pharmaceutical companies to 
reduce costs without any benefit for the patient community? 
We stress that this method of investigation is not aimed at replacing real 
life trials; rather, physical and computer experiments are two 
complementary sources of information with distinct roles and different 
degrees of cost, speed, and reliability. Simulation is usually cheaper and 
faster, and, what is more important, avoids the major ethical problems 
involved in clinical research, but in order to be of use, simulation must be 
fairly close to the physical set-up. What is the best way of integrating real 
and simulated trials to build actual knowledge while dynamically 
modifying the computer code to get closer and closer approximations to 
the reality? A virtual experiment may be part of a sequence in which 
simulations and physical observations play a part with alternating roles. 
The fundamental steps in designing such a mixed trial would consist of  
 designing  actual (small) trials that provide the physical data; 
 designing the simulated ones, to be run in groups, one after 
another, to improve our knowledge of the process; 
 choosing a “switching rule”: when do we change over from a 
virtual experiment to a real one to acquire more data, and vice-
versa? 
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 choosing a final stopping rule. 
To the best of our knowledge, this type of strategy has not yet been the 
object of theoretical investigation in a clinical research context. We are 
convinced that much work lies ahead. 
Last but not least, it is worth pointing out that although in the 
majority of cases the aim of a clinical trial is drug development, as shown 
in Section 2 there is a wide variety of additional areas of investigation that 
require trials on humans: in particular, new approaches to surgical and 
radiation therapies, physiotherapeutic treatments, new vaccines, new 
medical devices and test kits, new diagnostic tools and procedures, new 
methods of population screening, not to mention improving the quality of 
life: healthy eating, lifestyle changes, comfort for chronic illnesses, old 
age, etc. In all of them the practice of simulating experiments, wholly or 
partially, will sooner or later gather momentum. 
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